PE20001467A1 - Derivados de 4-fenilpiridina como antagonistas del receptor de neuroquinina - Google Patents

Derivados de 4-fenilpiridina como antagonistas del receptor de neuroquinina

Info

Publication number
PE20001467A1
PE20001467A1 PE2000000125A PE0001252000A PE20001467A1 PE 20001467 A1 PE20001467 A1 PE 20001467A1 PE 2000000125 A PE2000000125 A PE 2000000125A PE 0001252000 A PE0001252000 A PE 0001252000A PE 20001467 A1 PE20001467 A1 PE 20001467A1
Authority
PE
Peru
Prior art keywords
alkyl
phenylpyridine
derivatives
alcoxy
trifluoromethyl
Prior art date
Application number
PE2000000125A
Other languages
English (en)
Spanish (es)
Inventor
Quirico Branca
Michael Bos
Guido Galley
Heinz Stadler
Torsten Hoffmann
Walter Hunkeler
Patrick Schnider
Thierry Godel
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20001467A1 publication Critical patent/PE20001467A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
PE2000000125A 1999-02-24 2000-02-18 Derivados de 4-fenilpiridina como antagonistas del receptor de neuroquinina PE20001467A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99103504 1999-02-24
EP99123689 1999-11-29

Publications (1)

Publication Number Publication Date
PE20001467A1 true PE20001467A1 (es) 2000-12-20

Family

ID=26152908

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000125A PE20001467A1 (es) 1999-02-24 2000-02-18 Derivados de 4-fenilpiridina como antagonistas del receptor de neuroquinina

Country Status (54)

Country Link
US (2) US6297375B1 (enEXAMPLES)
EP (2) EP1035115B1 (enEXAMPLES)
JP (1) JP3399900B2 (enEXAMPLES)
KR (1) KR100384904B1 (enEXAMPLES)
CN (1) CN1142144C (enEXAMPLES)
AR (2) AR029614A1 (enEXAMPLES)
AT (2) ATE277905T1 (enEXAMPLES)
AU (1) AU767048B2 (enEXAMPLES)
BE (1) BE2015C057I2 (enEXAMPLES)
BG (1) BG64554B1 (enEXAMPLES)
BR (1) BRPI0000908B8 (enEXAMPLES)
CA (1) CA2299139C (enEXAMPLES)
CY (3) CY1111317T1 (enEXAMPLES)
CZ (1) CZ300596B6 (enEXAMPLES)
DE (3) DE60045564D1 (enEXAMPLES)
DK (2) DK1035115T3 (enEXAMPLES)
EA (1) EA003673B1 (enEXAMPLES)
EG (1) EG23817A (enEXAMPLES)
ES (3) ES2226622T3 (enEXAMPLES)
FR (2) FR2790473B1 (enEXAMPLES)
GB (1) GB2347422A (enEXAMPLES)
GE (1) GEP20022676B (enEXAMPLES)
GT (1) GT200000017A (enEXAMPLES)
HR (2) HRP20000097B1 (enEXAMPLES)
HU (1) HU227629B1 (enEXAMPLES)
IL (1) IL134654A (enEXAMPLES)
IS (1) IS2116B (enEXAMPLES)
IT (1) IT1320763B1 (enEXAMPLES)
JO (1) JO2294B1 (enEXAMPLES)
LT (1) LTC1035115I2 (enEXAMPLES)
LU (1) LU92745I2 (enEXAMPLES)
MA (1) MA26722A1 (enEXAMPLES)
ME (1) ME00593B (enEXAMPLES)
MY (2) MY147451A (enEXAMPLES)
NL (1) NL300758I1 (enEXAMPLES)
NO (1) NO315554B1 (enEXAMPLES)
NZ (1) NZ502948A (enEXAMPLES)
OA (1) OA11680A (enEXAMPLES)
PA (1) PA8491101A1 (enEXAMPLES)
PE (1) PE20001467A1 (enEXAMPLES)
PL (1) PL217311B1 (enEXAMPLES)
PT (2) PT1394150E (enEXAMPLES)
RS (3) RS50194B (enEXAMPLES)
SE (1) SE1035115T5 (enEXAMPLES)
SG (1) SG91856A1 (enEXAMPLES)
SI (1) SI1035115T1 (enEXAMPLES)
SK (2) SK287912B6 (enEXAMPLES)
SV (1) SV2002000024A (enEXAMPLES)
TN (1) TNSN00032A1 (enEXAMPLES)
TR (1) TR200000520A2 (enEXAMPLES)
TW (1) TWI288746B (enEXAMPLES)
UA (1) UA71547C2 (enEXAMPLES)
UY (1) UY32314A (enEXAMPLES)
ZA (1) ZA200000894B (enEXAMPLES)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3979099A (en) * 1998-05-11 1999-11-29 Philadelphia Health & Education Corporation (mct-1), a human oncogene
BR0008489A (pt) 1999-02-24 2002-02-05 Hoffmann La Roche Derivados de fenil- e piridinila
US6291465B1 (en) * 1999-03-09 2001-09-18 Hoffmann-La Roche Inc. Biphenyl derivatives
US6303790B1 (en) * 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
DE60006340T2 (de) * 1999-11-29 2004-09-09 F. Hoffmann-La Roche Ag 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramid
AUPQ514600A0 (en) 2000-01-18 2000-02-10 James Cook University Brain injury treatment
JP3938651B2 (ja) * 2000-04-13 2007-06-27 ă‚»ăƒłăƒˆăƒ©ăƒ«çĄć­æ ȘćŒäŒšç€Ÿ ć…‰ć­ŠæŽ»æ€§Î±âˆ’ăƒĄăƒăƒ«âˆ’ăƒ“ă‚čâˆ’ïŒ“ă€ïŒ•âˆ’ïŒˆăƒˆăƒȘăƒ•ăƒ«ă‚Șăƒ­ăƒĄăƒăƒ«ïŒ‰ăƒ™ăƒłă‚žăƒ«ă‚ąăƒŸăƒłăźèŁœé€ æ–čæł•
ME01311B (me) * 2000-07-14 2013-12-20 Hoffmann La Roche N-oksidi kao proljekovi 4-fenil-piridinskih derivata koji su antagonisti nki receptora
TWI287003B (en) * 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
TWI259180B (en) * 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
WO2002047663A1 (en) * 2000-12-14 2002-06-20 F. Hoffman-La Roche Ag Self emulsifying lipid matrix (selm)
US6531597B2 (en) 2001-02-13 2003-03-11 Hoffmann-La Roche Inc. Process for preparation of 2-phenyl acetic acid derivatives
WO2002076973A1 (fr) * 2001-03-27 2002-10-03 Eisai Co., Ltd. Derive d'amine cyclique a substitution n-aryle et medicament contenant ledit derive en tant que principe actif
KR100599134B1 (ko) * 2001-04-23 2006-07-12 에프. 혾프만-띌 ëĄœìŠˆ 아êȌ 양성 전늜선 ëč„대슝에 대한 -1 수용ìČŽ êžží•­ëŹŒì§ˆì˜ 용도
EP2266558B1 (en) * 2001-06-07 2017-04-19 Analgesic Neuropharmaceuticals, LLC Treatment of neuropathic pain with the N-methyl-D-aspartate (NMDA) receptor antagonist dextromethorphan
US20030083345A1 (en) * 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury
US6849624B2 (en) * 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides
JP4105091B2 (ja) * 2001-09-10 2008-06-18 ă‚šăƒ•ïŒŽăƒ›ăƒ•ăƒžăƒłâˆ’ăƒ© ăƒ­ă‚·ăƒ„ ă‚ąăƒŒă‚ČăƒŒ æČčæ€§ăƒă‚­ă‚œăƒˆăƒ­ăƒŒăƒ—æ€§é…ćˆç‰©
US7390813B1 (en) 2001-12-21 2008-06-24 Xenon Pharmaceuticals Inc. Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents
AU2003263402A1 (en) 2002-09-20 2004-04-08 Pfizer Products Inc. Amide and sulfonamide ligands for the estrogen receptor
US8729107B2 (en) * 2002-12-06 2014-05-20 Purdue Research Foundation Pyridines for treating injured mammalian nerve tissue
DE60329415D1 (de) * 2002-12-06 2009-11-05 Purdue Research Foundation Pyridine zur behandlung von verletztemsÀugetiernervengewebe
EP1592428B1 (en) * 2003-01-31 2007-07-11 F. Hoffmann-La Roche AG New crystalline modification of 2-(3,5-bis-trifluoromethyl-phenyl)-n- 6-(1,1-dioxo-1lamda-6 -thiomorpholin-4-yl)-4(4-fluoro-2-methyl-phenyl)-pyridin-3-yl -n-methyl-isobutyramide
RU2347777C2 (ru) 2003-07-03 2009-02-27 Đ€.Đ„ĐŸŃ„Ń„ĐŒĐ°ĐœĐœ-Ля Đ ĐŸŃˆ Аг ДĐČĐŸĐčĐœŃ‹Đ” Đ°ĐłĐŸĐœĐžŃŃ‚Ń‹ nk1/nk3 ĐŽĐ»Ń Đ»Đ”Ń‡Đ”ĐœĐžŃ ŃˆĐžĐ·ĐŸŃ„Ń€Đ”ĐœĐžĐž
US7288658B2 (en) * 2003-07-15 2007-10-30 Hoffmann-La Roche Inc. Process for preparation of pyridine derivatives
KR100934554B1 (ko) 2003-07-30 2009-12-29 제녌 파마슈티ìčŒìŠ€ ìžíŹ. í”ŒëŠŹë‹€ì§„ 유도ìČŽ 및 귞의 ìč˜ëŁŒì œëĄœì„œì˜ 용도
MX2007000198A (es) 2004-07-06 2007-03-15 Hoffmann La Roche Proceso para la preparacion de derivados de carboxamida-piridina utilizados como intermediarios en la sintesis de antagonistas del receptor nk-1.
WO2006014168A1 (en) * 2004-07-06 2006-02-09 Xenon Pharmaceuticals Inc. Nicotinamide derivatives and their use as therapeutic agents
KR100881240B1 (ko) * 2004-07-06 2009-02-05 에프. 혾프만-띌 ëĄœìŠˆ 아êȌ ïŒźïœ‹-1 수용ìČŽ Ꞟ항제의 합성에 있얎서 쀑간ìČŽëĄœì„œì‚Źìš©ë˜ëŠ” ìčŽë„Žëł”ìŠ€ì•„ëŻžë“œ í”ŒëŠŹë”˜ 유도ìČŽì˜ ì œìĄ° ë°©ëȕ
US20060030556A1 (en) * 2004-08-04 2006-02-09 Solvay Pharmaceuticals B.V. Neurokinin-1 receptor antagonists for the treatment of conditions responsive to testosterone elevation, including testosterone deficiency
WO2006013205A1 (en) * 2004-08-04 2006-02-09 Solvay Pharmaceuticals B.V. Neurokinin-1 receptor antagonists for the treatment of conditions responsive to testosterone elevation
US20060030600A1 (en) * 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
BRPI0515482A (pt) 2004-09-20 2008-07-22 Xenon Pharmaceuticals Inc derivados heterocĂŹclicos e seus usos como agentes terapĂȘuticos
JP4958786B2 (ja) 2004-09-20 2012-06-20 ă‚ŒăƒŽăƒłăƒ»ăƒ•ă‚ĄăƒŒăƒžă‚·ăƒ„ăƒŒăƒ†ă‚Łă‚«ăƒ«ă‚șăƒ»ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ 耇玠環èȘ˜ć°Žäœ“ăŠă‚ˆăłæČ»ç™‚è–Źăšă—ăŠăźăă‚Œă‚‰ăźäœżç”š
CN101083992A (zh) 2004-09-20 2007-12-05 æłœć†œćŒ»èŻć…Źćž æŠ‘ćˆ¶äșșçĄŹè„‚é…°CoAćŽ»é„±ć’Œé…¶çš„ć“’ć—ȘèĄç”Ÿç‰©
WO2006034338A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-coa desaturase
US8071603B2 (en) 2004-09-20 2011-12-06 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
TW200626138A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
JP4958784B2 (ja) 2004-09-20 2012-06-20 ă‚ŒăƒŽăƒłăƒ»ăƒ•ă‚ĄăƒŒăƒžă‚·ăƒ„ăƒŒăƒ†ă‚Łă‚«ăƒ«ă‚șăƒ»ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ ă‚čăƒ†ă‚ąăƒ­ă‚€ăƒ«âˆ’ïŒŁïœïŒĄăƒ‡ă‚”ăƒăƒ„ăƒ©ăƒŒă‚Œé…”çŽ ă«ă‚ˆăŁăŠćȘ’ä»‹ă•ă‚Œă‚‹ç–Ÿæ‚Łăźć‡ŠçœźăźăŸă‚ăźè€‡çŽ ç’°èȘ˜ć°Žäœ“
US7569725B2 (en) * 2004-10-21 2009-08-04 Britsol-Myers Squibb Company Anthranilic acid derivatives as inhibitors of 17ÎČ-hydroxysteroid dehydrogenase 3
WO2006060174A1 (en) * 2004-11-15 2006-06-08 Honeywell International Inc. Isocyanate-based polymer foams with nano-scale materials
KR100902425B1 (ko) * 2005-02-22 2009-06-11 에프. 혾프만-띌 ëĄœìŠˆ 아êȌ ïŒźïœ‹ïŒ‘ êžží•­ì œ
CN101128428A (zh) * 2005-02-24 2008-02-20 è©čæŁźèŻäžšæœ‰é™ć…Źćž 䜜äžșé’ŸçŠ»ć­é€šé“æ‰“ćŒ€ć‰‚çš„æ–°çš„ćĄć•¶èĄç”Ÿç‰©
NZ560232A (en) 2005-02-25 2010-11-26 Hoffmann La Roche Tablets with improved drug substance dispersibility
EP1863767B1 (en) * 2005-03-23 2009-03-11 F. Hoffmann-Roche AG Metabolites for nk-i antagonists for emesis
EP2540296A1 (en) 2005-06-03 2013-01-02 Xenon Pharmaceuticals Inc. Arminothiazole derivatives as human stearoyl-coa desaturase inhibitors
CA2618057A1 (en) * 2005-08-11 2007-02-22 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
HRP20110457T1 (hr) 2005-09-09 2011-07-31 Glaxosmithkline Llc Derivati piridina i njihova upotreba u liječenju psihotičnih poremećaja
PT1928427E (pt) * 2005-09-23 2010-03-01 Hoffmann La Roche Nova forma galénica
PT1945632E (pt) * 2005-11-08 2013-12-24 Vertex Pharma Moduladores heterocíclicos de transportadores de cassete de ligação a atp
US7671221B2 (en) * 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US7872022B2 (en) 2006-04-03 2011-01-18 Hoffmann-La Roche Inc. Serotonin transporter (SERT) inhibitors for the treatment of depression and anxiety
ES2554353T3 (es) 2006-04-07 2015-12-18 Vertex Pharmaceuticals Incorporated Moduladores de transportadores del casete de uniĂłn a ATP
USRE50453E1 (en) 2006-04-07 2025-06-10 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US7754739B2 (en) * 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
CN104447716A (zh) 2007-05-09 2015-03-25 æČƒæł°ć…‹æ–ŻèŻç‰©è‚Ąä»œæœ‰é™ć…Źćž Cftrè°ƒèŠ‚ć‰‚
RS55360B1 (sr) 2007-12-07 2017-03-31 Vertex Pharma Proces za proizvodnju cikloalkilkarboksiamido-piridin benzoevih kiselina
SG186638A1 (en) 2007-12-07 2013-01-30 Vertex Pharma Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
JP2011512413A (ja) * 2008-02-19 2011-04-21 ă‚°ăƒ©ă‚Żă‚œă‚čミă‚čă‚Żăƒ©ă‚€ăƒłăƒ»ăƒȘăƒŸăƒ†ăƒƒăƒ‰ăƒ»ăƒ©ă‚€ă‚ąăƒ“ăƒȘăƒ†ă‚Łăƒ»ă‚«ăƒłăƒ‘ăƒ‹ăƒŒ ïŒŠïœïœ‹ăźé˜»ćźłć‰€ăšă—ăŠăźă‚ąăƒ‹ăƒȘノピăƒȘゾン
CN106432213A (zh) 2008-02-28 2017-02-22 æČƒæł°ć…‹æ–ŻèŻç‰©è‚Ąä»œæœ‰é™ć…Źćž 䜜äžșcftrè°ƒèŠ‚ć‰‚çš„æ‚èŠłćŸșèĄç”Ÿç‰©
GB0808747D0 (en) 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
GB0814340D0 (en) * 2008-08-05 2008-09-10 Smithkline Beecham Corp Anhydrous crystol form fo a pyridine derivative
WO2011023733A1 (en) * 2009-08-27 2011-03-03 Glaxosmithkline Llc Anhydrate forms of a pyridine derivative
CA2778301C (en) 2009-11-18 2016-06-14 Helsinn Healthcare Sa Compositions comprising palonosetron and netupitant for treating nausea and vomiting
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
TW201143768A (en) * 2009-12-15 2011-12-16 Lundbeck & Co As H Pyridone derivatives as NK3 antagonists
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
WO2011127241A2 (en) 2010-04-07 2011-10-13 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
CA2795748C (en) 2010-04-07 2020-12-08 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
MX2012012204A (es) 2010-04-22 2012-12-05 Vertex Pharma Proceso para producir compuestos de cicloalquilcarboxamido-indol.
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
US8987307B2 (en) 2011-03-03 2015-03-24 Hoffmann-La Roche Inc. 3-amino-pyridines as GPBAR1 agonists
EP2736329A4 (en) * 2011-07-29 2015-03-25 Tempero Pharmaceuticals Inc COMPOUNDS AND METHODS
WO2013019635A1 (en) * 2011-07-29 2013-02-07 Tempero Pharmaceuticals, Inc. Compounds and methods
CN105412110B (zh) 2011-10-18 2018-05-25 è”«ć°”æŁźäżć„è‚Ąä»œć…Źćž 愈抄ćŒčćŠć’Œćž•æŽ›èŻșćžçŒçš„æČ»ç–—æ€§ç»„ćˆ
ES2622154T3 (es) 2011-11-08 2017-07-05 Vertex Pharmaceuticals Incorporated Moduladores de transportadores de cassete de uniĂłn atp-binding
US8426450B1 (en) * 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
HK1209318A1 (en) 2012-07-16 2016-04-01 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
CN105745198B (zh) * 2013-11-08 2018-09-21 æ©˜ç”ŸèŻć“ć·„äžšæ ȘćŒäŒšç€Ÿ 矧ç”ČćŸșć“Œć•¶èĄç”Ÿç‰©
EP3068392B9 (en) 2013-11-12 2021-08-04 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases
SG11201607670XA (en) 2014-04-15 2016-10-28 Vertex Pharma Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
WO2015171489A1 (en) * 2014-05-05 2015-11-12 Apicore Us Llc Methods of making netupitant and intermediates thereof
TWI649307B (zh) * 2014-05-07 2019-02-01 æ—„ć•†æ©˜ç”Ÿè—„ć“ć·„æ„­è‚Ąä»œæœ‰é™ć…Źćž Cyclohexylpyridine derivative
TW201613888A (en) * 2014-09-26 2016-04-16 Helsinn Healthcare Sa Crystalline forms of an NK-1 antagonist
RU2691136C2 (ru) 2014-11-18 2019-06-11 ВДртДĐșс Đ€Đ°Ń€ĐŒĐ°ŃŃŒŃŽŃ‚ĐžĐșалз Đ˜ĐœĐșĐŸŃ€ĐżĐŸŃ€Đ”ĐčтДЎ ĐĄĐżĐŸŃĐŸĐ± ĐżŃ€ĐŸĐČĐ”ĐŽĐ”ĐœĐžŃ ĐČŃ‹ŃĐŸĐșĐŸĐżŃ€ĐŸĐžĐ·ĐČĐŸĐŽĐžŃ‚Đ”Đ»ŃŒĐœĐŸĐč Ń‚Đ”ŃŃ‚ĐŸĐČĐŸĐč ĐČŃ‹ŃĐŸĐșĐŸŃŃ„Ń„Đ”ĐșтоĐČĐœĐŸĐč жОЎĐșĐŸŃŃ‚ĐœĐŸĐč Ń…Ń€ĐŸĐŒĐ°Ń‚ĐŸĐłŃ€Đ°Ń„ĐžĐž
RU2770050C2 (ru) 2015-03-04 2022-04-14 Đ’Đ°ĐœĐŽĐ° Đ€Đ°Ń€ĐŒĐ°ŃŃŒŃŽŃ‚ĐžĐșлз Đ˜ĐœĐș. ĐĄĐżĐŸŃĐŸĐ± Đ»Đ”Ń‡Đ”ĐœĐžŃ с ĐżŃ€ĐžĐŒĐ”ĐœĐ”ĐœĐžĐ”ĐŒ Ń‚Ń€Đ°ĐŽĐžĐżĐžŃ‚Đ°ĐœŃ‚Đ°
CN105061303A (zh) * 2015-08-03 2015-11-18 æˆéƒœæŹŁæ·é«˜æ–°æŠ€æœŻćŒ€ć‘æœ‰é™ć…Źćž äž€ç§ćˆ¶ć€‡ć„ˆćŠ„ćĄćŠć…łé”źäž­é—Žäœ“n-ç”ČćŸș-4-(2-ç”ČćŸșè‹ŻćŸș)-6-(4-ç”ČćŸș-1-擌ć—ȘćŸș)-3-搥敶èƒș的新æ–čæł•
EP4019018A1 (en) 2015-09-11 2022-06-29 Chase Pharmaceuticals Corporation Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
JPWO2017099049A1 (ja) * 2015-12-07 2018-09-27 ă‚­ăƒƒă‚»ă‚€è–Źć“ć·„æ„­æ ȘćŒäŒšç€Ÿ ïŒźïœ‹ïŒ‘ć—ćźčäœ“æ‹źæŠ—ć‰€
US12084472B2 (en) 2015-12-18 2024-09-10 Ardelyx, Inc. Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists
TWI773657B (zh) * 2015-12-18 2022-08-11 çŸŽć•†äșžćŸ·ćˆ©ć…‹æ–Żć…Źćž 䜜çˆČ非慹èș«ïœ”ïœ‡ïœ’ïŒ•äżƒæ•ˆćŠ‘äč‹ç¶“ć–ä»Łäč‹4-è‹ŻćŸșćĄć•¶ćŒ–ćˆç‰©
CN106892864A (zh) * 2015-12-21 2017-06-27 äžŠæ”·ç§‘èƒœèŻç‰©ç ”ć‘æœ‰é™ć…Źćž äž€ç§ć„ˆćŠ„çšźćŠæžžçŠ»çą±çš„æ™¶ćž‹aćŠć…¶ćˆ¶ć€‡æ–čæł•
AU2016377658B2 (en) 2015-12-22 2022-09-29 Endosome Therapeutics, Inc. Tripartite modulators of endosomal G protein-coupled receptors
IL312486B2 (en) 2017-04-10 2025-05-01 Chase Therapeutics Corp NK1 antagonist combination and method for treating synucleinopathies
HUE070223T2 (hu) 2017-06-30 2025-05-28 Chase Therapeutics Corp NK-1-antagonista készítmények és eljåråsok depresszió kezelésében történÔ alkalmazåsra
CN109384712B (zh) * 2017-08-14 2021-05-07 挗äșŹćźœćŽšćŒ»èŻç§‘æŠ€æœ‰é™ć…Źćž é¶ć‘nk1ć—äœ“æ‹źæŠ—ć‰‚ćŠć…¶ćœšćŒ–ç–—æ‰€è‡Žæ¶ćżƒă€ć‘•ćæȻ疗䞭的ćș”甚
EP3672964A4 (en) 2017-08-21 2021-05-26 Leiutis Pharmaceuticals Pvt. Ltd. Novel triple combination formulations for antiemetic therapy
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
AU2019348001B2 (en) * 2018-09-28 2023-09-21 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
US12351557B2 (en) * 2018-12-24 2025-07-08 Eustralis Pharmaceuticals Limited Chemical compound manufacture, new salt form, and therapeutic uses thereof
CN112174881B (zh) * 2019-07-04 2022-06-21 äžŠæ”·æŁźèŸ‰ćŒ»èŻæœ‰é™ć…Źćž äž€ç§ć„ˆćŠ„ćŒčćŠçš„èĄç”Ÿç‰©ćŠć…¶ćˆ¶ć€‡æ–čæł•
AU2020337177B2 (en) * 2019-08-23 2025-06-26 Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) Therapeutic methods and uses thereof
CN115427033B (zh) 2020-04-03 2024-08-09 ć°Œć°”ćŒ»ç–—æœ‰é™ć…Źćž 甹äșŽæȻ疗选è‡Șè„“æŻ’ç—‡ă€è„“æŻ’ç—‡äŒ‘ć…‹ă€æ€„æ€§ć‘ŒćžçȘ˜èż«ç»ŒćˆćŸ(ards)æˆ–ć€šć™šćź˜ćŠŸèƒœéšœçąç»ŒćˆćŸ(mods)çš„ç–Ÿç—…çš„nk-1ć—äœ“æ‹źæŠ—ć‰‚
AU2021285503A1 (en) 2020-06-02 2022-12-08 Nerre Therapeutics Limited Neurokinin (NK)-1 receptor antagonists for use in the treatment of pulmonary fibrosis conditions promoted by mechanical injury to the lungs
US12097197B2 (en) 2021-12-21 2024-09-24 Slayback Pharma Llc Stable liquid compositions of netupitant and palonosetron
EP4385497A1 (en) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Antioxidant-free fixed dose combination of netupitant and palonosetron
WO2024126408A1 (en) 2022-12-12 2024-06-20 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Antioxidant-free fixed dose combination of netupitant and palonosetron
EP4385500A1 (en) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Fixed dose combination comprising netupitant and palonosetron
WO2024126398A1 (en) 2022-12-12 2024-06-20 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Fixed dose combination comprising netupitant and palonosetron

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1557420A (en) 1977-03-10 1979-12-12 Soc D Etudes Prod Chimique Preparation of isobutyramide derivatives
KR810001320B1 (ko) 1977-03-17 1981-10-14 삐에넎 위람 신규한 ìŽì†Œë¶€í‹°ëŒëŻžë“œë„˜ì˜ ì œìĄ°ë°©ëȕ
KR810001697B1 (ko) 1978-02-06 1981-10-27 삐에넎 위람 ìŽì†Œë¶€í‹°ëŒëŻžë“œ 유도ìČŽì˜ 신규한 ì œìĄ°ë°©ëȕ
EP0089153B1 (en) 1982-03-17 1986-09-24 Smith Kline & French Laboratories Limited Pyridine derivatives
US4745123A (en) * 1986-02-18 1988-05-17 Warner-Lambert Company Substituted tetrahydro-3-pyridine-carboxylic acid, ester, and amide cholinergic agents
GB8607313D0 (en) 1986-03-25 1986-04-30 Ici Plc Pharmaceutical compositions
GB8607312D0 (en) 1986-03-25 1986-04-30 Ici Plc Therapeutic agents
CA1339423C (en) 1988-09-14 1997-09-02 Yuji Ono Pyridine compounds and pharmaceutical use thereof
US4994456A (en) 1989-03-01 1991-02-19 Nisshin Flour Milling Co., Ltd. Pyridinecarboxylic acid amide derivatives and pharmaceutical compositions comprising same
US4973597A (en) 1989-06-30 1990-11-27 Eli Lilly And Company Anticonvulsant agents
HU207047B (en) 1989-11-07 1993-03-01 Richter Gedeon Vegyeszet Process for producing new pyridine derivatives and pharmaceutical copositions comprising same
US5364943A (en) 1991-11-27 1994-11-15 Pfizer Inc. Preparation of substituted piperidines
GB9021056D0 (en) 1990-09-27 1990-11-07 Pfizer Ltd Antiarrhythmic agents
GB9214120D0 (en) 1991-07-25 1992-08-12 Ici Plc Therapeutic amides
US5719147A (en) * 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
WO1994003429A1 (en) 1992-07-31 1994-02-17 Merck Sharp & Dohme Limited Substituted amines as tachykinin receptor antagonists
US5387595A (en) 1992-08-26 1995-02-07 Merck & Co., Inc. Alicyclic compounds as tachykinin receptor antagonists
GB9305672D0 (en) 1993-03-19 1993-05-05 Wyeth John & Brother Ltd Amide derivatives
NZ264063A (en) 1993-08-13 1995-11-27 Nihon Nohyaku Co Ltd N-(2-phenylpyrid-3-yl)- and n-(4-phenylpyrimidin-5-yl)-n'-phenylurea derivatives and pharmaceutical compositions
IL111960A (en) 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
EP1462450B1 (en) * 1993-12-29 2007-06-13 MERCK SHARP & DOHME LTD. Substituted morpholine derivatives and their use as therapeutic agents
TW385308B (en) 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
CA2187531A1 (en) 1994-06-06 1995-12-14 David Christopher Horwell Tachykinin (nk1) receptor antagonists
US6294537B1 (en) 1995-03-17 2001-09-25 Sanofi-Synthelabo Compounds which are specific antagonists of the human NK3 receptor and their use as medicinal products and diagnostic tools
ES2194937T3 (es) * 1995-03-24 2003-12-01 Takeda Chemical Industries Ltd Compuestos ciclicos, su produccion y uso como antagonistas de los receptores de taquiquinina.
AR004735A1 (es) * 1995-11-24 1999-03-10 Smithkline Beecham Spa Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento.
IL125811A (en) 1996-03-29 2003-01-12 Pfizer 6-phenylpyridyl-2-amine derivatives, pharmaceutical compositions containing them and uses thereof in the preparation of a composition for inhibiting nos
WO1998021185A1 (fr) 1996-11-08 1998-05-22 Sankyo Company, Limited Arylurees ou derives d'arylmethylcarbamyle
US5972938A (en) 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
BR0008489A (pt) * 1999-02-24 2002-02-05 Hoffmann La Roche Derivados de fenil- e piridinila
DE60006340T2 (de) * 1999-11-29 2004-09-09 F. Hoffmann-La Roche Ag 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramid
US6303790B1 (en) * 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives

Also Published As

Publication number Publication date
ME00593B (me) 2015-08-31
MY123648A (en) 2006-05-31
HUP0000748A3 (en) 2003-12-29
ATE496032T1 (de) 2011-02-15
IT1320763B1 (it) 2003-12-10
ES2171109A1 (es) 2002-08-16
ES2171109B2 (es) 2003-09-16
EP1035115B1 (en) 2004-09-29
GB2347422A (en) 2000-09-06
NO20000885L (no) 2000-08-25
GEP20022676B (en) 2002-04-25
CN1142144C (zh) 2004-03-17
NL300758I2 (enEXAMPLES) 2015-12-22
PT1394150E (pt) 2011-02-17
HK1031223A1 (en) 2001-06-08
PA8491101A1 (es) 2001-04-30
IS5381A (is) 2000-08-25
HU227629B1 (en) 2011-10-28
ITMI20000328A1 (it) 2001-08-23
RS20080562A (en) 2009-09-08
FR2790473B1 (fr) 2004-04-02
JP2000247957A (ja) 2000-09-12
EG23817A (en) 2007-09-19
ES2359235T3 (es) 2011-05-19
ES2226622T3 (es) 2005-04-01
DK1394150T3 (da) 2011-03-21
HRP20000097A2 (en) 2001-10-31
AR029614A1 (es) 2003-07-10
KR100384904B1 (ko) 2003-05-22
SG91856A1 (en) 2002-10-15
SE1035115T3 (sv) 2005-01-18
KR20000062599A (ko) 2000-10-25
TWI288746B (en) 2007-10-21
AU1946800A (en) 2000-08-31
US6479483B2 (en) 2002-11-12
CY2015041I2 (el) 2016-06-22
NZ502948A (en) 2001-09-28
NO315554B1 (no) 2003-09-22
FR15C0049I2 (fr) 2016-02-12
SI1035115T1 (en) 2005-02-28
FR15C0049I1 (fr) 2015-08-28
CZ300596B6 (cs) 2009-06-24
ATE277905T1 (de) 2004-10-15
CA2299139C (en) 2011-03-29
MY147451A (en) 2012-12-14
CY1111317T1 (el) 2015-08-05
SE1035115T5 (sv) 2015-08-04
EP1394150A1 (en) 2004-03-03
CZ2000609A3 (cs) 2001-01-17
GT200000017A (es) 2001-08-15
SK287911B6 (sk) 2012-03-02
NO20000885D0 (no) 2000-02-23
AU767048B2 (en) 2003-10-30
US20020091265A1 (en) 2002-07-11
LU92745I2 (fr) 2015-08-17
BE2015C057I2 (enEXAMPLES) 2019-03-06
MA26722A1 (fr) 2004-12-20
ITMI20000328A0 (it) 2000-02-23
EP1394150B1 (en) 2011-01-19
YU9500A (sh) 2002-11-15
FR2790473A1 (fr) 2000-09-08
DE60014216T2 (de) 2006-03-02
CA2299139A1 (en) 2000-08-24
JO2294B1 (en) 2005-09-12
US6297375B1 (en) 2001-10-02
HUP0000748A2 (en) 2001-03-28
TR200000520A3 (tr) 2001-06-21
LTPA2015036I1 (lt) 2015-11-25
RS53869B1 (en) 2015-08-31
CY2015041I1 (el) 2016-06-22
MEP5709A (en) 2011-12-20
AR062949A2 (es) 2008-12-17
DE10008042A1 (de) 2000-08-31
DK1035115T3 (da) 2005-01-24
HU0000748D0 (en) 2000-04-28
CY2015042I1 (el) 2016-06-22
CN1270959A (zh) 2000-10-25
TNSN00032A1 (fr) 2005-11-10
IL134654A (en) 2011-03-31
HRP20000097B1 (en) 2008-12-31
BR0000908A (pt) 2000-09-12
DE60045564D1 (de) 2011-03-03
OA11680A (fr) 2005-01-12
SK2352000A3 (en) 2000-09-12
UY32314A (es) 2010-02-26
JP3399900B2 (ja) 2003-04-21
LTC1035115I2 (lt) 2017-04-10
RS50194B (sr) 2009-05-06
TR200000520A2 (tr) 2001-06-21
EP1035115A1 (en) 2000-09-13
HRP20080306B1 (hr) 2015-01-30
BG64554B1 (bg) 2005-07-29
PT1035115E (pt) 2005-01-31
DE60014216D1 (de) 2004-11-04
IL134654A0 (en) 2001-04-30
SV2002000024A (es) 2002-01-23
PL217311B1 (pl) 2014-07-31
ZA200000894B (en) 2000-08-24
GB0003908D0 (en) 2000-04-05
BRPI0000908B8 (pt) 2021-05-25
EA003673B1 (ru) 2003-08-28
IS2116B (is) 2006-06-15
NL300758I1 (enEXAMPLES) 2015-12-22
PL338598A1 (en) 2000-08-28
SK287912B6 (sk) 2012-03-02
EA200000155A3 (ru) 2000-12-25
EA200000155A2 (ru) 2000-08-28
BG104187A (en) 2000-11-30
HRP20080306A2 (en) 2008-11-30
BR0000908B1 (pt) 2013-09-24
UA71547C2 (uk) 2004-12-15

Similar Documents

Publication Publication Date Title
PE20001467A1 (es) Derivados de 4-fenilpiridina como antagonistas del receptor de neuroquinina
PE20010009A1 (es) Derivados de fenil - y piridinilo como antagonistas del receptor de la neuroquinina 1
PE20050482A1 (es) Derivados de dihidrobenzofuranilo alcanamida
PE20020258A1 (es) Derivados de 4-fenil-piridina como antagonistas del receptor de neuroquinina 1 (nk-1)
PE20030238A1 (es) Uso de los antagonistas del receptor nk-1 para el tratamiento de lesiones cerebrales, espinales y neuronales
ATE139233T1 (de) Annelierte thiophen-derivate, ihre herstellung und verwendung
PE20020721A1 (es) Derivados de quinuclidina como agentes antimuscarinicos m3
UY27029A1 (es) Nuevos derivados de pirazolpiridina sustituidos con piridina
PE20001551A1 (es) Derivados de eter biarilico como inhibidores de la recaptacion de monoaminas para el tratamiento de trastornos del snc
BR0306208A (pt) Compostos de dibenzilamina e seu uso farmacĂȘutico
PE20010741A1 (es) Derivados de piperazina como antagonistas de taquicininas
PE106499A1 (es) Antagonistas del receptor ccr-3
AR029616A1 (es) Compuestos derivados de 3-fenil-piridina, su uso, un proceso para prepararlos y medicamentos que los contienen
PE20000170A1 (es) Derivados benzosulfonas
DE69838662D1 (de) Morphinanderivate und ihre medizinische Anwendung
PE20020657A1 (es) Derivados de amida de piperidinas 1,4-disustituidas de formula (i)
PE20021072A1 (es) DERIVADOS DE DIHIDRO-BENZO(b) (1,4)-DIAZEPIN-2-ONA COMO ANTAGONISTAS I DE mGLUR2
ES2113081T3 (es) 1,4-benzotiazepinas utiles como agentes neurologicos.
PE20011114A1 (es) Decahidro-isoquinolinas
PE20040772A1 (es) Composicion y actividad antiviral de derivados de piperazina azaindoloxoaceticos
PE20040757A1 (es) Derivados de benzoxazina
ES2154605A1 (es) Nuevos derivados mixtos de bencimidazol-arilpiperazina con afinidad por los receptores serotoninergicos 5-ht1a y 5-ht3
JO2235B1 (en) Derivatives of phenyl
PE20040172A1 (es) Imidazolinilmetil aralquilsulfonamidas
PE20010649A1 (es) Derivados de antranilamida de piperidinas 1,4-di-sustituidas como antagonistas muscarinicos

Legal Events

Date Code Title Description
FG Grant, registration
MK Expiration of term